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Editor's Note: This is a lecture which was presented at Grand Rounds on October 30, 1992, at 
the Robert Packer Hospital. We are proud to present this paper in which Dr. Starzl discusses 
new information about chimerism and whole organ transplant. 
Throughout the modern history of transplantation, 
progress with kidney and liver grafting has been inter-
changeable, and then it became applicable, with very little 
change, to the thoracic organs and, most recently, to the 
intestine. I will focus today on why any kind of whole organ 
allograft and xenograft is accepted, because this defines not 
only the State of the Art for the liver but predicts the future 
of transplantation as a whole. 
My personal interest in transplantation came via the 
back door of physiology, during metabolic investigations of 
the special (so-called hepatotrophic) qualities of portal ven-
ous blood. In the course of these inquiries, I first developed 
a new experimental method of total hepatectomyI and then 
the operation ofliver replacement. 2 By the end of 1959, we 
had clarified the surgical secrets of liver transplantation and 
also had completed a second project in dogs with a multi-
visceral transplant procedure. 3 Twenty-five years later, this 
latter operation was performed successfully in humans and 
became the basis for several variations such as the cluster 
and liver-intestine procedures. 4 
Howe¥er, this research activity in 1958 through early 
1960, was in a therapeutic vacuum because there was no 
such thing as practical immunosuppression. Pharmacologic 
immunosuppression is dated to the classic paper on 6-mer-
captopurine by Schwartz and Dameshek5 in a non-transplant 
model. Within a few months, this drug was shown to pro-
long survival of skin grafts in rodents6•7 and kidney allo-
grafts in dogs. 8•9 Realizing by now that the road to my 
primary objective of liver transplantation would have to be 
through the simpler kidney transplant model, I moved from 
Northwestern University in Chicago to the University of 
Colorado in late 1961. There I began a clinical kidney 
program. 
Kidney Transplantation and Chimerism 
The program was based on the simple laboratory dis-
covery that canine kidney rejection under azathioprine could 
be reversed with prednisone in 88% of dogs, 10 an incident 
that proved to be the same in humans, as we reported in 
1963. II The key points were summarized in the title of the 
1963 article, the reversal of kidney rejection by steroids and 
the subsequent ability in successful cases to later reduce the 
intensity of immunosuppression (referred to as 
"tolerance' '). 
* Professor of Surgery, Director of Transplant Surgery, University of Pitts-
burgh, Pittsburgh, PA. 
49 
The explanation for these two observations was a mys-
tery in 1963, but in retrospect, a clue to the mystery was 
uncovered with exhaustive skin test studies (tuberculin, his-
toplasmin, coccidiodin, etc. performed on these early Col-
orado kidney recipients and their donors. Skin reactions that 
were positive in the donor but not in the recipient were 
found to cross over to the previously negative recipient along 
with the transplanted kidney 77% of the time. When this 
did not occur (the other 23%), it meant that the kidney 
transplant had failed. Kirkpatrick and Wilson, the immunol-
ogy fellows who performed these tests, speculated (as it 
turned out, correctly) that the migration of the skin tests was 
"caused by adoptive transfer of donor cellular immunity by 
leukocytes in the renal graft vasculature and hilar lymphoid 
tissue". 12 
That this actually had occurred was proved 29 years 
later when some of these original kidney recipients were 
restudied, proving that there had been an exchange of lym-
phodendritic leukocytes between the transplanted kidneys 
and their recipients. These cells still survived nearly three 
decades later. The presence of the donor cells in the lymph 
nodes and skin of four recipients of kidneys from HLA 
mismatched donors was shown with immunocytochemical 
techniques that stained the cells of donor phenotype. These 
appeared to be dendritic cells. The microchimerism was 
confirmed with polymerase chain reaction (PCR) tech-
niques. In a fifth patient, a female who had received a kid-
ney from her father, male donor cells with the Y 
chromosome were found in recipient tissues with fluorescent 
in situ hybridization, and these were confirmed with PCR. 
All of the studied recipients and their grafts were composite 
structures, no longer the same as at the outset. 13 
Liver Transplant Recipients 
This was only the beginning of what quickly became a 
scientific detective story. Between April and July of this 
year (1992), evidence was obtained that an even more exten-
sive exchange of tissue leukocytes occurred after liver trans-
plantation, creating a composite graft as well as chimeric 
composite host on an even larger scale than after kidney 
transplantation. 14 For the liver study, we began by obtaining 
follow-ups on all 44 of our first 206 liver recipients who still 
were alive 10 and 2/3 to nearly 23 years after transplanta-
tion. Six of these patients had stopped their immunosup-
pressive medications one to six years after transplantation 
and had been drug free for five to 13 years. The lymphocytes 
of treated as well as untreated patients reacted vigorously to 
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the lymphocytes of third party donors. The drug-free pa-
tients had achieved lasting immunologic tolerance. We also 
realized that many if not most of those still being treated 
probably no longer required immunosuppression. 
Multiple biopsies were performed on six of the drug 
free patients and on 16 more still under maintenance im-
munosuppression. Specimens were taken of the liver, skin, 
and a convenient lymph node. Using HLA markers, all 22 
were demonstrated to be chimeras by immunocytochemical 
and PCR techniques; by PCR, 754 also were blood chi-
meras. This also could be documented with sex typing in a 
subgroup of nine women who had received livers from male 
donors. Sex chimerism (the Y chromosome) was detected 
with fluorescent in situ hybridization or with PCR in every 
case. Using either the HLA alleles of chromosome 6 or rpe 
male Y chromosome, the hepatocytes, ducts, and endothe-
lial cells of the allografts remained donor specific while the 
Kupffer cells, dendritic cells, and other stromal leukocytes 
were those of the recipients. The systemic chimerism usu-
ally was in more than one site. In one female patient who 
lost her male graft after 12 years to recurrent viral hepatitis, 
tissue samples taken at retransplantation (which was suc-
cessful) showed male cells in blood, skin, lymph nodes, 
jejunum, and the aortic ellipse excised to accommodate a 
Carrell patch. At the time these samples were collected, this 
woman had been off medication for seven years. In the 
autopsy specimens from another patient who died of B virus 
hepatitis after 18.4 years, chimerism was found in essen-
tially all tissues of the body. 15 
Aside from their immunologic implications, the peri-
pheralized chimeric cells can profoundly alter metabolism. 16 
In three additional patients who had undergone liver trans-
plantation 26 to 91 months previously from metabolic stor-
age diseases, enzyme transport by the seeded peripheral 
cells explained how amylopectin (in two patients withGSD 
IV) could be absorbed from the heart as had occurred. Do-
nor cells (thought to be dendritic leukocytes) were detected 
with monoclonal anti HLA antibodies and peR in the myo-
cardium, skin, and lymph nodes. In a patient with Gauch-
er's disease, donor cells or donor DNA were found in the 
recipient blood, bone marrow, skin, small bowel, and 
lymph nodes. In this patient, the glucocerebroside deposits 
(Gaucher's cells) in the lymph nodes had diminished aston-
ishingly over the 26 months post-transplantation. 
Thus systemic chimerism was detected in all 25 liver 
recipients who were studied from two to more than 20 years 
post-transplantation. The ability to find donor cells wher-
ever they were looked for was striking. Because the same 
thing was found in the kidney recipients although less prom-
inently, we concluded that the same thing probably occurred 
with all kinds of grafts but so much more extensively with 
the liver than with other organs, that this accounted for what 
has been called hepatic tolerogenicity. 
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Why Principles of Immunosuppression 
Are Not Drug or Organ Specific 
These remarkable discoveries in kidney and liver recip-
ients were made only a few months ago. Of course, none of 
this was known in 1963 when, without knowing why, the 
observations of rejection reversal and so-called tolerance in 
kidney recipients led to the empiric therapeutic dogma upon 
which the transplantation of all whole organ transplantation 
is based. 11.17 The dogma calls for daily baseline treatment 
(in those early days with azathioprine) plus intervention 
with the highly dose-maneuverable adrenal cortical steroids 
(later augmented with antilymphoid agents) to whatever 
level is required to maintain stable graft function. This cre-
ates a trial and error situation for every patient as drugs are 
weaned. 
Although the new drugs that have been. added through 
the years have been increasingly potent, they can be viewed 
as traffic directors, allowing the cell movement to and from 
all kinds of grafts but preventing the immune destruction 
that is the natural purpose of the traffic. Apparently, it does 
not matter exactly how the immune reaction is disrupted, 
but only that this be achieved without killing all of the 
migratory cells. The emasculated but living cells that nor-
mally cause graft immunogenicity and rejection become in-
stead the missionaries subserving chimerism, graft 
acceptance, and ultimately tolerance. Disruption of the 
function of the lymphocyte can be at the levd of antigen 
processing (claimed for the experimental drug, deoxysper-
gualin), at an early stage in T-cell activation as occurs with 
cyclosporine and FK 506, or distal to this with rapamycin 
which does not inhibit the secretion of cytokines including 
IL2 but blocks their action. The so-called antiproliferative 
drugs (of which azathioprine was the prototype) work even 
more distally. 
Reexamining 'fransplantation Immunology 
With the understanding that cell migration and repop-
ulation is the basis of graft acceptance, no matter what the 
organ, we now can ree~amine some controversies in trans-
plantation immunology that have never been resolved, in-
cluding why HLA tissue matching to govern the distribution 
of cadaveric organs has been so imperfect a tool. To under-
stand these controversies, we must turn the pages back 50 
years to when Peter Medawar planted the seed of our clinical 
specialty. If rejection was an immunologic response as Me-
dawar claimed in 1944,18 what could be more logical in 
preventing it than to weaken the immune system. By 1951, 
Billingham, Krohn, and Medawar19 and the American, Mor-
gan,20 had taken this crucial step and had shown that skin 
graft survival was prolonged with cortisone acetate and 
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ACTH, the first immunosuppressive drugs. The year before, 
Dempster of Hammersmith showed mitigation of skin graft 
rejection with total body irradiation. 21 
Seemingly, these were small steps, but then in 1953, 
Billingham, Brent, and Medawar22,23 raised expectations to 
a new level by showing the possibility of acquiring immu-
nologic tolerance, albeit only under the special circum-
stance of inoculation of immunocompetent adult spleen 
cells into fetal and perinatal mice. Prehn and Main24 were 
able to mimic these developmental conditions in adult mice 
using supralethal total body irradiation and bone marrow 
alIa-reconstitution. When the reconstituted mice were 
shown to be tolerant to donor strain- skin, the clinical pos-
sibility of creating radiation bone marrow chimeras as a 
means to the end of solid organ transplantation seemed 
obvious. 
These hopes were promptly dashed when the concept 
of graft versus host disease (GVHD) and runt disease was 
delineated by Billingham and Brent. 25 However, what was 
not clearly recognized then or later was that these whole 
animal models, and subsequently the experimental Fl hybrid 
model, are almost artifacts in the sense that the interactions 
of the two-way cell migration and repopUlation that I have 
been discussing were precluded in each case: by the imma-
ture state of one party (that was the Billingham, Brent, 
Medawar model), by the cytoablation used by Main and 
Prehn (and later bone marrow transplanters), or by genetic 
manipulation (the F1 hybrid model). These were whole ani-
mal analogues of the in vitro-one-way mixed-lymphocyte 
reaction. 
Division of Transplantation into Two Fields 
Of course, this is hindsight 33 years later. Between 
1959 and 1963, and without really knowing why, the intel-
lectual root that came from Medawar's seed divided into 
two branches. Although the issue from the roots looked like 
two separate trees when they surfaced, the differences 
merely reflected different therapeutic dogmas. The bone 
marrow tree with its precondition of cytoablation mimicked 
the Billingham, Brent, Medawar model and was the in vivo 
version of a one-way mixed lymphocyte reaction (MLR). 
HLA matching was crucial. Engraftment in a drug free state 
(called tolerance) was a realizable Objective only with per-
fect matching. This was not achieved clinically until 
1968,26.27 but even with major histocompatibility complex 
(MHC) compatibility, GVHD was a constant threat. The 
reason for the virulence of the GVHD with an HLA mis-
match was the complete removal of a counter weight to the 
transplanted immunocytes. 
The whole organ transplanters who had broken ranks 
with their bone marrow colleagues, empirically developed 
the long term immunosuppressive, which I discussed ear-
lier, with which success (called graft acceptance, not toler-
ance) did not depend on matching and could be 
accomplished without GVHD, even after the transplantation 
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of lymphoid-rich organs such as the intestine and liver. The 
explanation for the GVHD resistance with the whole organs 
is envisioned as the interaction of cells coming out from the 
allograft with the immunocytes of the recipient (a two-way 
in vivo MLR), the term for the long term coexistence of two 
populations of cells in mixed chimerism. 
Of course, the fact that mixed chimerism interdicts 
GVHD is only half of the story. The other half is that the 
mid-field cell interaction (which results in what we have 
called mutual natural immunosuppression) also mitigates 
rejection (the host versus graft reaction). The details of this 
donor-recipient rapprochement are not known, but it does 
seem clear that even organs like the kidney, with a poor 
lymphoreticular constituency, have enough dendritic cells 
(or whatever these leukocytes are) to sometimes induce for 
themselves donor-specific non-reactivity (tolerance). In the 
process, the donor/recipient interactions are envisioned as 
occurring on a sliding scale in which each further level of 
histoincompatibility provokes variable countervailing in-
creases in the mutually-cancelling donor versus recipient 
and recipient versus donor cell reactivity. 
For renal allografts, it becomes possible to understand 
why Terasaki, Opelz, and others have shown a large advan-
tage only for 6-antigen matched cadaver kidney but not for 
any matching that is less perfect. Most importantly, it be-
comes possible to understand why the vast majority of un-
matched kidneys do well. For liver transplantation, the 
reports from Cambridge and Pittsburgh become comprehen-
sible that have shown an inverse relation between the quality 
of HLA match and survival of liver recipients but again a 
difference that is measurable only within a few percentage 
points. 
Induction of Tolerance 
It seems obvious that the crucial variable distinguishing 
one organ from another is the lymphodendritic (not the pa-
renchymal) component and that these tissue leukocytes can 
be tolerogenic as well as immunogenic when effective im-
munosuppression is given. The liver with its dense constit-
uency of these cells is high on the favorable list of 
tolerogenicity with the lung and intestine following and the 
heart and kidney bringing up the rear. It is self evident that 
the underprivileged kidney and heart could be brought to 
the same level of tolerogenicity advantage as the liver by the 
peri operative infusion of lymphoreticular cells obtained 
from bone marrow of the organ donor or possibly from the 
spleen. Now, the cycle is coinplete because this was the 
starting point for Billingham, Brent, and Medawar, and then 
Main and Prehn. 
The Drug Revolution 
Of course, what I have said today is our current under-
standing of transplantation. Rather than limiting a search for 
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better drugs, this insight should encourage their develop-
ment, as can be illustrated by the different eras of liver 
transplantation. In July 1967, the first long-surviving liver 
recipients were produced under azathioprine and predni-
sone, after an effort which by then had consumed almost 10 
years. However, acceptance of the procedure was slow over 
the next dozen years because of its high mortality. Roy 
CaIne's introduction of cyclosporine28 and the subsequent 
combination of this drug with prednisone29 allowed a dou-
bling or more of survival about a decade ago and brought 
Ii ver transplantation to center stage. 30 
Recently, the liver has been the lead organ in the next 
step of immunosuppression, made possible with the drug, 
FK 506, whose action is 'similar to cyclosporine. 31 The pa-
tient and graft survival with FK 506 has been improved a 
further 10% to 15% compared to the cyclosporine results in 
the Pittsburgh trials and in the recent European multicenter 
randomized trials of FK 506 versus cyclosporine. 
These trials suggest that we are at the dawn of another 
era in transplantation. This is signaled, in addition, by an 
emerging population of recipients of complete cadaveric 
small bowel, either transplanted alone, with the liver, or as 
part of a multi visceral graft.32 Of 23 such patients treated 
four months to more than two years ago, all but three are 
alive. Only one example of GVHD has been seen. The 
chimerism I have been discussing has been obvious in every 
case. In the intestine epithelial cells of the graft remain those 
of the donor while the lymphoreticular stromal substrate 
switches over to predominantly that of the recipient. 
Xenotransplantation 
When organs are transplanted from a significantly dis-
parate species, the first inununologic hurdle is that of pre-
formed xenospecific antibodies which quickly devascularize 
the graft and exclude it from recipient circulation by dam-
aging its blood vessels. 33 If this barrier can be surmounted, 
the process of xenograft acceptance involves the same bi-
directional cell migration and consequent systemic chimer-
ism as with allotransplantation. After hamster to rat 
xenotransplantation, the cells displaced from the xenografts 
can be detected in widespread rat recipient tissues with poly-
clonal rat absorbed antihamster leukocyte antibodies and 
confirmed with polymerase chain reaction (PCR) tech-
niques. 14 As with allotransplantation, the chimerism is more 
extensive after liver than after heart transplantation. 
Chimerism was observed recently in a patient who sur-
vived for 70 days after receipt of a baboon liver. Death was 
caused by infectious complications and by complications of 
biliary stasis rather than rejection or GVHD.34 This means 
that successful clinical xenotransplantation must be visual-
ized along the same lines of donor-recipient cellular inti-
macy which we believe is the fundamental means of 
xenograft as well as allograft acceptance. 
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Summary 
I have tried to present a unified view of transplantation 
to which the liver has continued the central role. 35 ,36 Thank 
you for the honor of allowing me to present this to you. 
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